Sanofi (SNY) Tops Q1 EPS by EUR0.20

Sanofi (NASDAQ: SNY) reported Q1 EPS of EUR1.63, EUR0.20 better than the analyst estimate of EUR1.43. Revenue for the quarter came in at EUR8.97 billion versus the consensus estimate of EUR8.83 billion.

Full-year 2020 business EPS(2) guidance affirmed:

• Sanofi continues to expect 2020 business EPS(2) to grow around 5%(3) at CER, barring unforeseen major adverse events. Sanofi expects the favorable first-quarter COVID-19 impact on sales and business EPS to be mainly offset during the second quarter. Applying average April 2020 exchange rates, the currency impact on 2020 business EPS is estimated to be between -1% to -2%

For earnings history and earnings-related data on Sanofi (SNY) click here.

You May Also Be Interested In

• Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
• Rivian reports Q3 2026 production of 19,751 vehicles
• ConAgra Brands (CAG) Tops Q1 EPS by 13c, Beats on Revenue; Offers FY27 EPS Guidance